Eevia Health publishes information memorandum regarding the rights issue

Eevia Health Plc, (”Eevia” or ”The Company”) publishes an information memorandum regarding the invitation to subscribe for shares in Eevia today. The information memorandum, including conditions and instructions for the rights issue, is available on the Company's website:  https://eeviahealth.com.

The offer, if fully subscribed, is expected to provide Eevia with SEK 28.6 million before deduction of expenses related to the offer. The Rights Issue is secured through subscription commitments corresponding to approximately 10.8 percent of the offer volume, and guarantee commitments of approximately 39.4 percent of the offer volume, resulting in 50.2 percent in total.

Briefly about the rights issue:

• All shareholders registered in Eevia’s shareholder register maintained by Euroclear Finland or Euroclear Sweden on the record date of June 13, 2024, will be allocated one (1) subscription right for each share held.
• Three (3) such subscription rights entitle subscription of four (4) new shares. The subscriber will receive one (1) Warrant of series TO1 per each four (4) subscribed and paid offer shares.
• Subscription of shares will commence on June 14, 2024, in Sweden and on July 18, 2024, in Finland and is expected to end on June 28, 2024, in Sweden and on July 2, 2024, in Finland
• The subscription price is SEK 0.60 per share.
• The company will approximately receive SEK 28.6 million upon full subscription of the rights issue.
• Trading in subscription rights is ongoing from and including June 14, 2024, until and including June 25, 2024.

Advisers

Partner Fondkommission is acting as the financial adviser and issuing agent in Sweden for the rights issue. OP Bank is the issuing agent in Finland.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                             Joel Westerström, Partner Fondkommission

Email: stein.ulve@eeviahealth.com                        Email: joel.westerstrom@partnerfk.se

Telephone: +358 400 22 5967                                 Telephone:   +46 735 11 68 53

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia’s other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.

To learn more, please visit www.eeviahealth.com  or follow Eevia Health on LinkedIn@EeviaHealth.